Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue 4, 2009, Pages 298-303

  Berker, Dilek ^a,c   Işik, Serhat ^a   Canbay, Alper ^b   Yusuf, Aydin ^a   Tütüncü, Yasemin ^a   Delibaşi, Tuncay ^a   Güler, Serdar ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Cardiology Clinic   (Turkey)

^c NONE   (Turkey)

Author keywords

Antithyroid drugs; Atrial fibrillation; Graves' disease; P wave dispersion

Indexed keywords

PROPRANOLOL; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; HYPERTHYROIDISM; MALE; P WAVE; P WAVE DISPERSION; P WAVE DURATION; RANDOMIZED CONTROLLED TRIAL; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTITHYROID AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; GRAVES DISEASE; HEART CONDUCTION SYSTEM; HUMANS; MALE; METHIMAZOLE; PROPYLTHIOURACIL; PROSPECTIVE STUDIES; THYROID HORMONES;

EID: 70349386501     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Frost L, Engholm G, Moller H, Husted S. Decrease in mortality in patients with a hospital diagnosis of atrial fibrillation in Denmark during the period 1980-1993. Eur Heart J 1999; 20: 1592-9.
2. Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 1982; 307: 1165-70.
3. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
4. Staffurth JS, Gibberd JS, Tang FS. Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J 1977; 2: 688-90.
5. Sawin CT, Geller A, Wolf P, Belanger A, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-52.
6. Watanabe H, Ma M, Washizuka T, Komura S, Yoshida T, Hosaka Y, et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun 2003; 308: 439-44.
7. Maciel B, Gallo L, Marin Neto J, Maciel L, Martins L. Autonomic control of heart rate during dynamic exercise in human hyperthyroidism. Clin Sci 1988; 75: 209-15.
8. Aras D, Maden O, Özdemir O, Aras S, Topaloǧlu S, Yetkin E, et al. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol 2005; 99: 59-64.
9. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905-17.
10. Katircibaşi MT, Deniz F, Pamukçu B, Binici S, Atar I. Effects of short-term propylthiouracil treatment on p wave duration and p wave dispersion in patients with overt hypertyroidism. Exp Clin Endocrinol Diabetes 2007; 115: 376-9.
11. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131: 790-5.
12. Abe A, Yamamoto T, Isome M, Ma M, Yaoita E, Kawasaki K, et al. Thyroid hormone regulates expression of Shaker-related potassium channel mRNA in rat heart. Biochem Biophys Rapid Comm 1998; 245: 226-30.
13. Dudley SC, Baumgarten CM. Bursting of cardiac sodium channels after acute exposure to 3,5,3′-triiodo-L-thyronine. Circ Res 1993; 73: 301-13.
14. Poliker R Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993; 87: 1435-41.
15. Johnson PN, Fredberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated rabbits. Cardiology 1973; 58: 273-89.
16. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
17. Dillmann W. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88: 626-30.
18. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of "idiopathic" atrial fibrillation. Am J Cardiol 1979; 44: 9-12.
19. Çetinarslan B, Akkoyun M, Cantürk Z, Tarkun I, Kahraman G, Komşuoǧlu B. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism. Endocr Pract 2003; 9: 200-3.
20. Güray Y, Güray Ü, Yilmaz MB, Altay H, Kisacik H, Güler S, et al. P wave duration and P wave dispersion in hyperthyroidism: effect of antithyroid treatment. Türk Kardiyol Dern Arş 2004; 32: 556-63.
21. Agner T, Almdal T, Thorsteinsson B, Agner E. A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull 1984; 31: 157-9.
22. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clin Endocrinol 1999; 50: 127-32.
23. Walker J, Crawford F, Kato S, Spinale F. The novel effects of triiodo-L-thyronine on myocyte contractile function and betaadrenergic responsiveness in dilated cardiomyopathy. J Cardiovasc Surg 1994; 108: 672-9.
24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
25. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997; 157: 441-5.
26. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156: 409-16.
27. Ariyarajah V, Mercado K, Apiyasawat S, Puri P, Spodick DH. Correlation of left atrial size with p-wave duration in interatrial block. Chest 2005; 128: 2615-8.